Todays Report: The Algert Global LLC Buys 14,266 Shares of SciClone Pharmaceuticals Inc. (SCLN)

The Algert Global LLC Buys 14,266  Shares of SciClone Pharmaceuticals Inc. (SCLN)

Algert Global LLC bought a new position in shares of SciClone Pharmaceuticals Inc. (NASDAQ:SCLN) during the third quarter, Holdings Channel reports. The fund bought 14,266 shares of the specialty pharmaceutical company’s stock, valued at approximately $146,000.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in SCLN. Suntrust Banks Inc. boosted its position in SciClone Pharmaceuticals by 3.8% in the second quarter. Suntrust Banks Inc. now owns 11,938 shares of the specialty pharmaceutical company’s stock worth $155,000 after buying an additional 432 shares in the last quarter. Nationwide Fund Advisors boosted its position in SciClone Pharmaceuticals by 1.7% in the second quarter. Nationwide Fund Advisors now owns 41,262 shares of the specialty pharmaceutical company’s stock worth $539,000 after buying an additional 708 shares in the last quarter. TFS Capital LLC boosted its position in SciClone Pharmaceuticals by 4.0% in the second quarter. TFS Capital LLC now owns 41,018 shares of the specialty pharmaceutical company’s stock worth $536,000 after buying an additional 1,580 shares in the last quarter. ProShare Advisors LLC boosted its position in SciClone Pharmaceuticals by 4.2% in the second quarter. ProShare Advisors LLC now owns 44,398 shares of the specialty pharmaceutical company’s stock worth $580,000 after buying an additional 1,784 shares in the last quarter. Finally, BlackRock Group LTD boosted its position in SciClone Pharmaceuticals by 3.7% in the second quarter. BlackRock Group LTD now owns 83,233 shares of the specialty pharmaceutical company’s stock worth $1,087,000 after buying an additional 2,994 shares in the last quarter. 81.03% of the stock is currently owned by hedge funds and other institutional investors.

SciClone Pharmaceuticals Inc. (NASDAQ:SCLN) traded up 0.49% on Friday, hitting $10.20. The stock had a trading volume of 228,059 shares. The firm’s 50 day moving average price is $9.76 and its 200-day moving average price is $11.23. The stock has a market cap of $520.74 million, a PE ratio of 14.57 and a beta of 1.65. SciClone Pharmaceuticals Inc. has a 12 month low of $7.36 and a 12 month high of $15.02.

In other SciClone Pharmaceuticals news, CFO Wilson Wai-Shun Cheung sold 149,962 shares of the firm’s stock in a transaction that occurred on Wednesday, October 26th. The shares were sold at an average price of $10.00, for a total value of $1,499,620.00. Following the transaction, the chief financial officer now directly owns 15,064 shares of the company’s stock, valued at approximately $150,640. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Nancy T. Chang sold 25,040 shares of the firm’s stock in a transaction that occurred on Tuesday, August 30th. The stock was sold at an average price of $10.30, for a total transaction of $257,912.00. Following the completion of the transaction, the director now directly owns 29,019 shares in the company, valued at $298,895.70. The disclosure for this sale can be found here. 7.63% of the stock is currently owned by corporate insiders.

SciClone Pharmaceuticals Company Profile

SciClone Pharmaceuticals, Inc is a pharmaceutical company. The Company’s product portfolio of therapies includes oncology, infectious diseases and cardiovascular disorders. The Company operates in two segments: China and the Rest of the World, including its operations in the United States and Hong Kong.

Related posts

Leave a Comment